Management Team

  • Biresh Roy

    Chief Executive Officer

    Former Chief Financial Officer of Verona Pharma plc, a listed clinical stage bio-pharmaceuticals group.

    Mr Roy is a strategic executive with a track record in executing and financing international M&A deals and delivering turnarounds, mainly in the bio-pharmaceuticals sector. He has acted as CFO for several biotech and medical device companies including Enigma Diagnostics, Xytis, Morphochem and Santhera.

    Prior to this, he was a management consultant at A.T. Kearney and PwC leading international teams in large scale projects for big pharma and private equity backed pharmaceutical companies

    Mr Roy qualified as a Chartered Accountant with Price Waterhouse and holds a B.Sc. in economics from the London School of Economics

  • Dr. R. Garraway

    Chief Operating Officer

    • Dr. Garraway has over 30 years’ experience in developing, funding and commercialising novel technologies in the healthcare and bioscience sectors and is one of the founders of PBB.
    • He is an experienced director of technology companies both as a managing partner of private equity and VC funds, and also from 6 years at Imperial Innovations plc (now IP Group plc), heading their biotechnology incubator, creating, funding and mentoring companies with novel intellectual property. Prior to this he was an investment banker in the healthcare and FMCG M&A teams at JPMorgan and Robert Flemings investment banks.
    • Dr. Garraway holds a Ph.D. in biological sciences from the University of Portsmouth and an MBA from the London Business School.
  • Dr Sam Yurdakul

    Director of Development and Regulatory Affairs

    • Dr Yurdakul has more than 30 years’ experience in leading product development from concept, through regulatory approval to commercialisation for major healthcare and consumer products companies including, Chiron Biopharma (Novartis), Boots Healthcare and Procter & Gamble. He has deep therapeutic area expertise in haemophilia and pain management, as well as experience in dermatology and infectious diseases.
    • Dr Yurdakul holds a Ph.D. in Physical Chemistry from Imperial College, London.
  • Justin Bowen

    General Counsel

    • Former General Counsel for ten years at Imperial Innovations Group plc, a London listed spin-off from Imperial College London investing in biotech and industrial start-ups from leading scientific research universities in the UK.
    • Mr Bowen is an experienced director of legal affairs and company secretary, focussing particularly on corporate, financing and commercial matters mainly in the private equity and venture capital sectors. He has previously also acted as General Counsel at RAC plc and prior to that was a legal adviser at GEC plc. Mr Bowen qualified as a Barrister at Lincoln’s Inn, specialising in corporate and trust matters.

  •